Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis

Area of Science:

• Neuroscience
• Psychiatry
• Medical Technology

Background:

• Treatment-resistant depression (TRD) poses a significant clinical challenge.
• Vagus nerve stimulation (VNS) is an emerging neuromodulatory treatment for TRD.
• Existing evidence on VNS for TRD is mixed, necessitating further analysis.

Purpose of the Study:

• To conduct an updated meta-analysis on the efficacy and safety of adjunctive Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD).
• To synthesize findings from controlled studies comparing VNS with control groups in TRD patients.

Main Methods:

• Systematic screening and analysis of controlled studies on adjunctive VNS for TRD.
• Meta-analysis of efficacy (response rates) and safety (discontinuation, adverse events) using RevMan 5.3.
• Inclusion of three controlled studies with 1048 TRD patients (622 VNS, 426 control).

Main Results:

• Adjunctive VNS demonstrated significantly superior study-defined response rates compared to the control group (SMD: 1.96, P < 0.00001).
• Voice alteration was a more frequent adverse event in the VNS group.
• No significant difference in discontinuation rates due to any reason between VNS and control groups (RR: 0.50, P = 0.34).

Conclusions:

• Adjunctive Vagus Nerve Stimulation (VNS) is an effective and relatively safe treatment option for Treatment-Resistant Depression (TRD).
• Voice alteration is a notable side effect requiring consideration.
• Further high-quality randomized controlled trials are warranted to solidify the role of VNS in TRD management.